Journal
VIRCHOWS ARCHIV
Volume 482, Issue 5, Pages 905-910Publisher
SPRINGER
DOI: 10.1007/s00428-022-03400-w
Keywords
COVID-19; COVID-19 vaccine; COVID-19-related lymphadenopathy; Mimicker of lymphoma
Categories
Ask authors/readers for more resources
COVID-19 vaccine can cause lymphadenopathy which may resemble metastasis or cancer recurrence. This case report describes the histopathologic features of persistent lymphadenopathy in a breast cancer patient following a COVID-19 vaccine booster. Although the histological features mimic follicular lymphoma, the findings were ultimately interpreted as a reactive lesion associated with the timing of COVID-19 vaccine administration, rather than true lymphoma.
There has been a surge in COVID-19 vaccine-associated lymphadenopathy (LAD), including after the booster dose of vaccine. This can create diagnostic dilemmas in oncology patients as the relatively sudden LAD can mimic metastasis or cancer recurrence, at a risk of leading to additional but unnecessary anti-neoplastic therapy. Here we report the histopathologic features in a case of persistent LAD occurring in a patient with history of breast invasive ductal carcinoma which followed a COVID-19 vaccine booster. A needle core and then excisional biopsy showed atypical follicular hyperplasia with features that histologically and phenotypically could mimic follicular lymphoma, but the findings were ultimately interpreted to be reactive in nature and related temporally to COVID-19 vaccine. To our knowledge, this is the first case of an atypical lymphoproliferative lesion with features potentially mimicking lymphoma associated with COVID-19 vaccine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available